PL3362449T3 - Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową - Google Patents

Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową

Info

Publication number
PL3362449T3
PL3362449T3 PL16781455T PL16781455T PL3362449T3 PL 3362449 T3 PL3362449 T3 PL 3362449T3 PL 16781455 T PL16781455 T PL 16781455T PL 16781455 T PL16781455 T PL 16781455T PL 3362449 T3 PL3362449 T3 PL 3362449T3
Authority
PL
Poland
Prior art keywords
preventing
disorders associated
treating disorders
sibiriline
derivatives
Prior art date
Application number
PL16781455T
Other languages
English (en)
Inventor
Marie-Thérèse DIMANCHE-BOITREL
Stéphane BACH
Claire DELEHOUZE
Yvette Mettey
Peter Goekjian
Arnaud COMTE
Original Assignee
Institut National De La Santé Et De La Recherche Médicale (Inserm)
Centre National De La Recherche Scientifique (Cnrs)
Universite De Poitiers
Sorbonne Université
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Santé Et De La Recherche Médicale (Inserm), Centre National De La Recherche Scientifique (Cnrs), Universite De Poitiers, Sorbonne Université, Universite Claude Bernard Lyon 1 filed Critical Institut National De La Santé Et De La Recherche Médicale (Inserm)
Publication of PL3362449T3 publication Critical patent/PL3362449T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10Preservation of living parts
    • A01N1/12Chemical aspects of preservation
    • A01N1/122Preservation or perfusion media
    • A01N1/126Physiologically active agents, e.g. antioxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
PL16781455T 2015-10-13 2016-10-13 Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową PL3362449T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306624 2015-10-13
PCT/EP2016/074638 WO2017064217A1 (en) 2015-10-13 2016-10-13 Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
EP16781455.7A EP3362449B1 (en) 2015-10-13 2016-10-13 Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis

Publications (1)

Publication Number Publication Date
PL3362449T3 true PL3362449T3 (pl) 2021-12-13

Family

ID=54337712

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16781455T PL3362449T3 (pl) 2015-10-13 2016-10-13 Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową

Country Status (6)

Country Link
US (1) US10426758B2 (pl)
EP (1) EP3362449B1 (pl)
DK (1) DK3362449T3 (pl)
ES (1) ES2885474T3 (pl)
PL (1) PL3362449T3 (pl)
WO (1) WO2017064217A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3788045T2 (ro) 2018-05-03 2023-09-30 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
HRP20231381T1 (hr) 2018-05-03 2024-03-01 Rigel Pharmaceuticals, Inc. Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
JP7493586B2 (ja) 2019-09-06 2024-05-31 ライジェル ファーマシューティカルズ, インコーポレイテッド Rip1阻害化合物ならびにそれを作製および使用するための方法
CA3149926A1 (en) 2019-09-06 2021-03-11 Yan Chen Rip1 inhibitory compounds and methods for making and using the same
SI4055021T1 (sl) 2019-11-07 2026-02-27 Rigel Pharmaceuticals, Inc. Heterociklične spojine, ki inhibirajo rip1
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI840311B (zh) 2020-07-01 2024-04-21 美商雷傑製藥公司 Rip1k抑制劑
WO2022157392A1 (en) * 2021-01-25 2022-07-28 Seabelife Use of indole, 6- and 7-azaindole derivatives as inhibitors of ferroptosis regulated cell death
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
KR20250127084A (ko) 2022-12-02 2025-08-26 시비라이프 조절된 괴사 억제제와 n-아세틸시스테인의 상승작용적 조합
WO2025078659A1 (en) 2023-10-12 2025-04-17 Seabelife Method and kit for inducing cell differentiation, and regulated necrotic cell death inhibitor for use for regenerating damaged tissues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP2384753B1 (en) 2003-08-29 2016-01-06 The Brigham and Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
US8148361B2 (en) * 2006-11-10 2012-04-03 Bristol-Myers Squibb Company Kinase inhibitors
AU2011248175A1 (en) * 2010-05-06 2012-10-25 Merck Sharp & Dohme Corp. Aza-Indole derivatives useful as modulators of FAAH
MX365640B (es) * 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
TW201613916A (en) * 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
WO2017064216A1 (en) * 2015-10-13 2017-04-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) N1- and n7-substituted sibiriline derivatives and their use as inhibitor of cellular necroptosis

Also Published As

Publication number Publication date
WO2017064217A1 (en) 2017-04-20
US20180325876A1 (en) 2018-11-15
DK3362449T3 (da) 2021-07-19
ES2885474T3 (es) 2021-12-13
EP3362449B1 (en) 2021-06-16
EP3362449A1 (en) 2018-08-22
US10426758B2 (en) 2019-10-01

Similar Documents

Publication Publication Date Title
PL3362449T3 (pl) Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową
IL256501B (en) Causes, uses and methods of treating synuclein pathology
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
IL259570A (en) Combined therapy and their uses and methods
IL255780A (en) Therapeutic combinations and methods for treating neoplasia
IL253656A0 (en) Mono- and polyazanephthalene modified histories and their use
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL252560B (en) Heterocyclic derivatives and their uses
GB2588261B (en) Apparatus, use of the apparatus and arrangement
GB201512733D0 (en) Therapeutic agents for treating conditions associated with elevated GDF15
IL257820A (en) Aminoglycosides for the treatment of genetic diseases
IL271728A (en) Materials, uses and treatment methods
ZA201604611B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PT3166945T (pt) Derivados de triazolopirimidinona ou de triazolopiridinona inovadores e utilização dos mesmos
SG10201912843YA (en) Sleep improving agent
ZA202002526B (en) New alcoxyamino derivatives for treating pain and pain related conditions
PL3386988T3 (pl) Nowe pochodne dihydropiranopirymidynonu i ich zastosowanie
PT3268356T (pt) Compostos heterocíclicos e métodos para a sua utilização
SG11201610349SA (en) Dosing regimens for treating and/or preventing cerebral amyloidoses
IL255012A0 (en) Preparations and methods for treating skin conditions
GB2545167B (en) Cloches and use thereof
GB201500278D0 (en) Novel combination and use
AU2014903677A0 (en) Treating and/or preventing psoriasis